title: Persistent generation of thrombin after acute myocardial infarction.
abstract: During the acute phase of myocardial infarction, the generation of thrombin is reflected in the sudden rise of fibrinopeptide A (FPA) and the thrombin-antithrombin III (TAT) complex in blood. We have systematically determined the FPA and TAT plasma concentrations over a period of 14 days after acute myocardial infarction in 100 patients. Mean levels of both thrombin markers were the highest on admission, remained elevated over the following few days, and then gradually declined after day 5. Still, by the end of the first week two thirds of the patients had distinctly elevated TAT and FPA levels, and by the end of the second week such an abnormality was present in half of them. Continuous intravenous heparin infusion at a dose of 20,000 units/day, administered for 1 week to patients who had either received (n = 21) or not received (n = 17) streptokinase, led to a significant depression (p less than 0.05) of thrombin markers over the first 48 hours, an effect that did not persist over the subsequent days of treatment. In patients not assigned to heparin treatment, those in heart failure had significantly (p less than 0.05) higher mean TAT and FPA values on days 3, 5, and 7 compared with patients in whom heart failure was absent. Infarct extension, pulmonary embolism, and death were also associated with a rise in one or both thrombin markers, often preceding the onset of clinical symptoms. Thrombinogenesis was not accompanied by changes in mean plasma concentrations of prothrombin, antithrombin III, or alpha 2-macroglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Copernicus Academy of Medicine, Kraków, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Szczeklik
authors.forename: J
authors.initials: J
authors.lastname: Dropinski
authors.forename: J
authors.initials: J
authors.lastname: Radwan
authors.forename: M
authors.initials: M
authors.lastname: Krzanowski
mesh_terms: D000990:Antithrombin III / Q000032:analysis*; D005260:Female; D005344:Fibrinopeptide A / Q000032:analysis*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D010447:Peptide Hydrolases / Q000032:analysis*; D013300:Streptokinase / Q000627:therapeutic use; D013917:Thrombin / Q000096:biosynthesis*
chemical_list: C046193:antithrombin III-protease complex; D005344:Fibrinopeptide A; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D013300:Streptokinase; D013917:Thrombin